MONTRÉAL, March 21, 2024 /CNW/ – Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is deeply disappointed with the draft recommendations of the Canadian Drug Expert Committee (CDEC) issued by the Canadian Agency for Drugs and Technologies in Health (CADTH) for LEQVIO® (inclisiran).
As an organization, Novartis respects the process conducted by CADTH but at the same time holds a firm belief in the value that LEQVIO brings to patients, clinicians, and the healthcare system. Globally, LEQVIO is widely accessible in 94 countries,4 with public reimbursement in 31 countries,5 and has positively impacted over 178,000 patients.5
https://www.cadth.ca/open-calls-input-and-feedback-0
